Exenatide
The first GLP-1 receptor agonist ever approved (2005), derived from Gila monster venom — historically important, rarely used today.
Exenatide began the entire GLP-1 era. Researchers found that exendin-4, a peptide in Gila monster saliva, activated human GLP-1 receptors while resisting breakdown; the synthetic version, exenatide, was approved for type 2 diabetes in 2005 as Byetta (twice daily) and later Bydureon (weekly).
Its weight effects were small — a few kilograms — but it proved the mechanism was safe and druggable, opening the path to liraglutide, semaglutide, and tirzepatide. Both brands have since been discontinued or marginalized; exenatide survives mainly in pharmacology lectures and in the origin story told whenever someone asks how lizard venom led to the biggest weight-loss drugs in history.
This glossary entry is general information, not medical advice, and is written to be consistent with FDA prescribing information and primary trial publications as of its last review. Always consult a licensed healthcare provider for personal medical decisions.
Questions about Exenatide? Ask a doctor free.
A licensed doctor can apply this to your health history in a free telehealth consultation — booking takes about two minutes, with programs from $149/month. You're only charged after approval.
Book an Appointment